OncoMed Granted Fundamental Patent for Identifying Therapeutics Targeting Cancer Stem Cells
Complete the form below to unlock access to ALL audio articles.
OncoMed Pharmaceuticals has announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,115,360 titled "Isolation and Use of Solid Tumor Stem Cells."
"Our latest patent provides us with important intellectual property as we develop new means for designing and testing therapies that target cancer stem cells," commented John Lewicki, Ph.D., Senior Vice President Research and Development.
"We believe that our approach using isolated and purified cancer stem cells will be a better predictor of the efficacy of new cancer therapeutics compared with current conventional approaches in cancer research."
The patent covers OncoMed's proprietary approach for testing of cancer stem cell therapeutics to inhibit human tumor growth in preclinical models.
The patented method enables OncoMed to identify potential cancer therapeutics that inhibit tumor growth following injection of cancer stem cells obtained from a patient's tumor.
"Our latest patent covers an important tool for identifying and testing new cancer therapeutics. Using this novel technology, OncoMed is evaluating a number of potential cancer therapeutics," said Paul Hastings, OncoMed's President and Chief Executive Officer.
"The issuance of this patent underscores the significant technological advances we have made in isolating cancer stem cells and using these cells to discover new cancer therapeutics."
"Our patent portfolio covering cancer stem cell technology is broad and emphasizes OncoMed's leadership position in cancer stem cell technology and the development of new therapeutics targeting those cells."
